izpis_h1_title_alt

Cell models for Alzheimer’s and Parkinson’s disease : at the interface of biology and drug discovery
ID Cetin, Sandra (Author), ID Knez, Damijan (Author), ID Gobec, Stanislav (Author), ID Kos, Janko (Author), ID Pišlar, Anja (Author)

.pdfPDF - Presentation file, Download (1,65 MB)
MD5: 86A0A1CC400C802BB1FF16A54A9D8C08
URLURL - Source URL, Visit https://www.sciencedirect.com/science/article/pii/S0753332222003134 This link opens in a new window

Abstract
Neurodegenerative diseases are severely debilitating conditions characterized primarily by progressive neuronal loss and impairment of the nervous system. Alzheimer’s and Parkinson’s diseases are the most common neurodegenerative disorders, and their impact is increasing as average life expectancy increases worldwide. Although the underlying mechanisms of both progressive diseases have been extensively studied, we still lack a comprehensive understanding of the molecular basis of both diseases. Current therapeutic options do not slow the progression of the diseases and only provide symptom relief. Cell models that resemble the characteristics of the disease in question are important in drug discovery projects because they provide information about the therapeutic benefits of drugs under development. Here, we review current in vitro cell models used to study the molecular basis of Alzheimer’s and Parkinson’s disease focusing on their potential for discovering of disease-modifying therapeutics to combat neurodegenerative diseases. We discuss phenotypic screening as an important approach for identifying novel therapeutic molecules. Advances in the development of cell-based assays for drug discovery are discussed, ranging from simple monoculture cell models to high-throughput three-dimensional cell models. Finally, we critically present the limitations of cell models and the caveats encountered in drug discovery to find effective treatment for neurodegenerative diseases.

Language:English
Keywords:neurodegenerative diseases, cell models, cytotoxicity assays, drug discovery, drug screening
Work type:Article
Typology:1.02 - Review Article
Organization:FFA - Faculty of Pharmacy
Publication status:Published
Publication version:Version of Record
Year:2022
Number of pages:11 str.
Numbering:Vol. 149, art. 112924
PID:20.500.12556/RUL-139099 This link opens in a new window
UDC:615.4:54:616.831-003.8
ISSN on article:1950-6007
DOI:10.1016/j.biopha.2022.112924 This link opens in a new window
COBISS.SI-ID:105487619 This link opens in a new window
Publication date in RUL:30.08.2022
Views:869
Downloads:160
Metadata:XML RDF-CHPDL DC-XML DC-RDF
:
Copy citation
Share:Bookmark and Share

Record is a part of a journal

Title:Biomedicine & pharmacotherapy
Publisher:Elsevier
ISSN:1950-6007
COBISS.SI-ID:23136261 This link opens in a new window

Licences

License:CC BY-NC-ND 4.0, Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International
Link:http://creativecommons.org/licenses/by-nc-nd/4.0/
Description:The most restrictive Creative Commons license. This only allows people to download and share the work for no commercial gain and for no other purposes.

Secondary language

Language:Slovenian
Keywords:nevrodegenerativne bolezni, celični modeli, preskusi citotoksičnosti, odkrivanje zdravil, Alzheimerjeva bolezen, Parkinsonova bolezen, farmacevtska kemija

Projects

Funder:ARRS - Slovenian Research Agency
Project number:P4-0127
Name:Farmacevtska biotehnologija: znanost za zdravje

Funder:ARRS - Slovenian Research Agency
Project number:J3-9267
Name:Zaviranje aktivnosti katepsina X kot nov pristop za zdravljenje Parkinsonove bolezni

Funder:ARRS - Slovenian Research Agency
Project number:P1-0208
Name:Farmacevtska kemija: načrtovanje, sinteza in vrednotenje učinkovin

Funder:ARRS - Slovenian Research Agency
Project number:Z1-1859
Name:Kovalentni zaviralci: zaviranje monoamin oksidaze preko nekatalitskih aminokislinskih ostankov

Similar documents

Similar works from RUL:
Similar works from other Slovenian collections:

Back